Abiopharma

🔍 BUECHLER KENNETH F (Director)

Company: QuidelOrtho Corp (QDEL)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 15,532 shares of Restricted Stock Units (Equity Grant) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,532.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 12,204 shares of Restricted Stock Units (Converted) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,204.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 3,661 shares of Restricted Stock Units (Premium) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,661.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• F2: The restricted stock units will vest on June 25, 2027.
• F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
• F4: 3,051 shares vested on June 25, 2026, 3,051 shares will vest on September 25, 2026, 3,051 shares will vest on December 25, 2026, and 3,051 shares will vest on March 25, 2027.